ociparstat

**Ociparstat** (OCIParstat) is a synthetic polysaccharide, specifically a low molecular weight heparin derivative, designed as a potent, selective, and reversible inhibitor of human heparanase (HPSE), an enzyme overexpressed in various cancers and inflammatory conditions that promotes tumor metastasis, angiogenesis, and inflammation by degrading heparan sulfate in the extracellular matrix. Developed by **Chimerix** (formerly from Ophirium Pty Ltd acquisition), it is primarily being investigated for **acute respiratory distress syndrome (ARDS)** associated with severe COVID-19 and other causes, aiming to block heparanase-mediated vascular leak, endothelial dysfunction, and coagulopathy. Administered intravenously, it has advanced to **Phase 3** trials (e.g., SPARTA trial, NCT05170348), showing promising safety and efficacy signals in reducing mortality and organ failure in critically ill patients.